

# PCL Department Publications - 2002

## "A,B,C,D"

Francis J, Jung B, Zhang G, Cheng J, Ho W, **Burnham WM**, Eubanks JH: Kindling induces the mRNA expression of methyl DNA-binding factors in the adult rat hippocampus. *Neuroscience* 113: 79-87 (2002).

Thavendiranathan P, Chow C, Cunnane S, **Burnham WM**: The effect of the classic ketogenic diet on animal seizure models. *Brain Research* 959: 206-213 (2002).

Edwards HE, Dortok D, Tam J, Won D, **Burnham WM**: Prenatal Stress Alters Seizure Thresholds and the Development of Kindled Seizures in Infant and Adult Rats. *Hormones Behavior* 42: 437-447 (2002).

Likhodi SS, **Burnham WM**: On the anticonvulsant effect of acetone and the ketogenic diet. *Epilepsia* 43: 1596 (2002).

**Burnham WM** : Epilepsy. In: Encyclopedia of Cognitive Science. Nature publishing group. 2: 1-7(2002).

**Burnham WM** : Why are complex partial seizures intractable? In: Burnham WM, Carlen PL, and Hwang PA, (eds). Intractable Seizures Diagnosis, Treatment and Prevention. Plenum Press, 2002, New York, pp. 107-110

---

Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, **Busto UE**: Probing brain reward system function in Major Depressive Disorder: Altered response to d-amphetamine. *Arch Gen Psychiatry* 59: 409-416 (2002).

Cardenas L, Tremblay LE, Naranjo CA, Herrmann N, Zack M, **Busto UE**: Brain reward system activity in major depression and comorbid nicotine dependence. *J Pharmacol Exp Ther* 302: 1265-1271 (2002).

## "E,F,G"

**George SR**, O'Dowd BF, Lee SR: G-protein-coupled receptor oligomerization and its potential for drug discovery. *Nature Reviews Drug Discovery* 1: 808-820 (2002).

Lamey M, Thompson M, Varghese G, Chi H, Sawzdargo M, **George SR**, O'Dowd BF: Distinct residues in the carboxyl tail mediate agonist-induced desensitization and internalization of the human dopamine D-1 receptor. *J Biol Chem* 277:9415-9421 (2002).

Levac BAR, O'Dowd BF, **George SR**: Oligomerization of opioid receptors: generation of novel signaling units. *Curr Opin Pharmacol* 2: 76-81 (2002).

Lee DK, **George SR**, O'Dowd BF: Novel G protein-coupled receptor genes expressed in the brain: Continued discovery of important therapeutic targets. *Expert Opin Therap Targets* 6:185-202, (2002).

Demchyshyn LL, O'Dowd BF, **George SR**: Structure of mammalian D1 and D5 dopamine receptors and their function and regulation in cells. In: Sidhu A, Laruelle M, Vernier P, (eds). Dopamine Receptors and Transporters. Marcel Dekker, New York, 2002.

---

Lam V, Findley HW, Reed JC, Freedman MH and **Goldenberg GJ**: Comparison of DR5 and Fas expression levels relative to the chemosensitivity of acute lymphoblastic leukemia cell lines. *Leukemia Res.* 26: 503-513 (2002).

---

Basrani B, Santos JM, Tjaderhane L, **Grad H**, Gorduysus O, Huang J, Lawrence HP, Friedman S: Substantial antimicrobial activity in chlorhexidine-treated human root dentin. *Oral Surg Oral Med Oral Pathol Oral Radiol Endon* 94: 240-245 (2002).

---

## "H"

**Haas DA**: An update on analgesics for the management of acute postoperative dental pain. *J Can Dental Assoc* 68: 476-482 (2002).

**Haas DA**: An update on local anesthetics in dentistry. *J Can Dental Assoc* 68: 546-551 (2002).

Shojaei AR, **Haas DA**: Local anesthetic cartridges and latex allergy: a literature review. *J Can Dental Assoc* 68: 603-607 (2002).

**Haas DA**: Emergency Drugs. *Dental Clin North Amer* 46: 815-830 (2002).

**Haas DA**: Drugs in Dentistry. *Compendium Pharmac Specialties* L26-29 (2002).

---

Rosemond E, Peltekova V, Naples M, Thogersen H, **Hampson DR**: Molecular determinants of high affinity binding to group III metabotropic glutamate receptors. *J Biol Chem* 277: 7333-7340 (2002).

---

Harper PA, Wong JMY, Lam MSM, Okey AB: Polymorphisms in the human AH receptor. *Chem-Biol Interactions* 141:161-187 (2002).

---

## "I, J"

Jorge-Nebert LF, Eichelbaum M, Griese E-U, **Inaba T**, Arias TD: Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype employing caffeine. *Pharmagenetics* 12: 39-45 (2002).

Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, **Inaba T**, Azuma J: Novel detection assay by PCR-RFLP and frequency of CYP3A5 SNPs, CYP3A5\*3 and \*6, in a Japanese population. *Pharmacogenetics* 12: 331-334 (2002).

Matsumoto S, Ding LR, Ishii M, Fischer NE, **Inaba T**: The interaction of human and bovine serum proteins with CYP3A in human liver microsomes: inhibition of testosterone 6beta-hydroxylation by albumin, alpha-globulins, alpha-1-acid glycoprotein and gamma-globulins. *Tox Letters* 136: 33-41 (2002).

Fukuen S, Fukuda T, Matsuda H, Sumida A, Yamamoto I, **Inaba T**, Azuma J. Identification of the novel splicing variants for the hPXR in human livers. *Biochem Biophys Res Comm* 298: 433-438 (2002).

---

Costei A, Kozer E, Ho T, **Ito S**, Koren G. Perinatal outcome following third trimester exposure to paroxetine. *Arch Ped Adoles Med*. 156:1129-1132 (2002).

---

## "K"

Khanna JM, Morato GS, **Kalant H**: Effect of NMDA antagonists, agonists, an NMDA agonist, and serotonin depletion on acute tolerance to ethanol. *Pharmacol Biochem Behav*: 72: 291-298 (2002).

**Kalant H**: Editorial: Tolérance et dépendance - une entité commune, ou distinctive pour chaque drogue? *Alcoolologie et Addictologie* 24: 204-206 (2002)

**Kalant H**: Addiction. In: Adelman G, Smith BH (eds.). *Encyclopedia of Neuroscience*, 3rd ed. New York: Elsevier Science (2002).

---

**Kalow W:** Both populations and individuals are evolutionary targets: Pharmacogenomic and cultural indicators. *The Pharmacogenomics Journal*. 2: 12-19 (2002).

**Kalow W:** Pharmacogenetics and personalized medicine. *Fund Clin Pharmacol* 16: 337-342 (2002).

Sy SKB, Ciaccia A, Li W, Roberts EA, Okey A, **Kalow W**, Tang BK: Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. *Eur J Clin Pharmacol* 58: 357-365 (2002).

Sy SKB, Tang BK, Johnston JA, Roberts EA, **Kalow W:** Multivariate cluster analysis of a human hepatic cytochrome P450 database. *Eur J Clin Pharmacol* 58: 554-562 (2002).

---

**Khanna JM**, Morato GS, Kalant H: Effect of NMDA antagonists, antagonists, an NMDA agonist, and serotonin depletion on acute tolerance to ethanol. *Pharmacol Biochem Behav* 72: 291-298 (2002).

---

**Kish SJ:** How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? *Pharmacol Biochem Behav* 71: 845-855 (2002).

Ross BM, Moszczynska A, Peretti FJ, Adams V, Schmunk GA, Kalasinsky KS, Ang L, Mamalias N, Turenne SD, **Kish SJ:** Decreased activity of brain phospholipid metabolic enzymes in human users of cocaine and methamphetamine. *Drug Alcohol Depend* 67: 73-79 (2002).

Fitzmaurice P, Ang L, Guttman M, Rajput A, Furukawa Y, **Kish SJ:** Brain aconitase activity is not decreased in progressive supranuclear palsy. *Neurology* 59:137-138 (2002).

Furukawa Y, Kapatos G, Haycock JW, Worsley J, Wong H, **Kish SJ**, Nygaard TG: Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia. *Annals Neurology* 51:637-641 (2002).

Furukawa Y, Vigouroux S, Wong H, Guttman M, Rajput AH, Ang L, Briand M, **Kish SJ**, Briand Y: Brain proteosomal function in sporadic Parkinson's disease and related disorders. *Annals Neurology* 51:779-782 (2002).

---

**Koren G**, Cohn T, Chitayat D, Kapur B, Remington G, Reid DM, Zipursky RB: Use of Atypical Antipsychotics During Pregnancy and the Risk of Neural Tube Defects in Infants. *Am J Psychiatry*. 159: 136-137 (2002).

**Koren G**, Cohn T, Chitayat D, Kapur B, Remington G, Reid DM, Zipursky RB: Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. *Op cit*. 159: 136-7 (2002)

Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, **Koren G**: Child development following exposure to TCA of fluoxetine throughout fetal life: a prospective, controlled study. *Op cit*. 159: 1189-95 (2002).

**Koren G**, Boskovic R, Hard M, Maltepe C, Navioz Y, Einarson A: Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. *Am J Obstet Gynecol*. 185: S228-31 (2002).

Magee LA, Chandra K, Mazzotta P, Stewart D, **Koren G**, Guyatt GH: Development of a health-related quality of life instrument for nausea and vomiting of pregnancy. *Op cit* 185: S323-8 (2002).

**Koren G**, Levichek Z: The teratogenicity of drugs for nausea and vomiting of pregnancy: perceived versus true risk. *Op cit*. 185: S248-52 (2002).

Magee LA, Mazzotta P, **Koren G**: Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy. (NVP). *Op cit*. 185: S256-61 (2002)

Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, **Koren G**: Aspirin consumption during the first trimester of pregnancy and congenital anomalies: A meta-analysis. *Op cit*. 187: 1623-30 (2002).

**Koren G**: Drinking alcohol while breastfeeding. Will it harm my baby? *Can Fam Physician*. 48:39-41 (2002).

Chandra K, Einarson A, **Koren G**: Taking ginger for nausea and vomiting during pregnancy. *Op cit* 48:1441-2 (2002).

Goldman RD, **Koren G**: Influenza vaccination during pregnancy. *Op cit* 48: 1768-9 (2002).

Yagev Y, **Koren G**: Eating fish during pregnancy. Risk of exposure to toxic levels of methylmercury. *Op cit* 48:1619-21 (2002).

Levichek Z, Atanackovic G, Oepkes D, Maltepe C, Einarson A, Magee L, **Koren G**: Nausea and vomiting of pregnancy. Evidence based treatment algorithm. *Op cit*. 48: 267-8 (2002).

Liaschko A, **Koren G**: Cystic fibrosis during pregnancy. *Op cit* 48: 463-4 (2002).

Abadi S, Einarson A, **Koren G**: Use of warfarin during pregnancy. *Op cit* 48: 695-7 (2002).

Einarson A, **Koren G**: Bacterial vaginosis during pregnancy. Should we screen for and treat it? *Op cit.* 48: 877-8 (2002).

Einarson A, Portnoi G, **Koren G**: Update on Motherisk. Seven years of questions and answers. *Op cit.* 48:1301-4 (2002).

Ratnapalan S, **Koren G**: Taking ACE inhibitors during pregnancy. Is it safe? *Op cit* 48:1047-9 (2002).

**Koren G**, Chan D, Klein J, Karaskov T: Estimation of fetal exposure to drugs of abuse, environmental tobacco smoke, and ethanol. *Ther Drug Monit.* 24: 23-25 (2002).

Kozer E, Parvez S, Minassian BA, Kobayashi J, Verjee Z, **Koren G**: How high can we go with phenytoin? *Op cit* 24: 386-9 (2002).

Kapur B, Soldin OP, **Koren G**: Potential prevention of neural tube defects by assessment of women of childbearing age through monitoring of folate. *Op cit* 24: 628-30 (2002).

Nevin AC, Parshuram C, Nulman I, **Koren G**, Einarson A: A survey of physicians knowledge regarding awareness of maternal alcohol use and the diagnosis of FAS. *BMC Fam Pract.* 3: 2 (2002).

**Koren G**: Trends of medication errors in hospitalized children. *J Clin Pharmacol* 42: 707-10 (2002).

**Koren G**, Money D, Boucher M, Aoki F, Petric M, Innocencion G, Wolosk M, Remple V, Pelland F, Geist R, Ho T, Bar-Oz B, Loebstein R: Serum concentrations, efficacy, and safety of a new intravenously administered varicella zoster immune globulin in pregnant women. *Op cit* 42: 267-74 (2002).

Schmid R, **Koren G**, Klein J, Katz J: The stability of a ketamine-morphine solution. *Anesth Analg.* 94: 898-900 (2002).

Taddio A, Gurguis MG, **Koren G**: Lidocaine-Prilocaine Cream Versus Tetracaine Gel for Procedural Pain in Children. *Ann Pharmacother.* 36:687-692 (2002).

Hemels ME, **Koren G**, Einarson TR: Increased use of antidepressants in Canada: 1981-2000. *Op cit* 36:1375-9 (2002).

**Koren G**: SSRI's in Pregnancy-Are they safe? *Pediatr Res.* 51: 424-425 (2002).

Koren L, Mokady O, Karaskov T, **Koren G**, Geffen E: A novel method using hair for determining hormonal levels in wildlife. *Animal Behavior* 63: 403-6 (2002).

**Koren G**, Klinger G, Ohlsson A: Fetal Pharmacotherapy. *Drugs* 62:757-73 (2002).

Bailey B, Forget S, **Koren G**: Pregnancy outcome of women who failed appointments at a teratogen information service clinic. *Reprod Toxicol.* 16: 77-80 (2002).

**Koren G**: Ethical framework for observational studies of medicinal drug exposure in pregnancy. *Teratology* 65:191-5 (2002).

**Koren G**: Comment on antiepileptics and antipsychotics. *Op cit* 66: 273 (2002).

Sgro MD, Barozzino T, Mirghnai HM, Moscato L, Akoury H, **Koren G**, Chitayat DA: Pregnancy outcome post renal transplantation. *Op cit.* 65: 5-9 (2002).

Aleksa K, **Koren G**: Ethical issues in including pediatric cancer patients in drug development trials. *Pediatr Drugs.* 4: 257-65 (2002).

Freedman B, **Koren G**: Reliability of maternal reporting in identifying major congenital malformations. *Vet Hum Toxicol.* 44:180-1 (2002).

Nikfar S, Abdollahi M, Moretti ME, Magee LA, **Koren G**: Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. *Dig Dis Sci.* 47: 1526-9 (2002).

**Koren G**: Adverse effects of assisted reproductive technology and pregnancy outcome. *Pediatr Res.* 52: 136 (2002).

Chandra K, Magee L, **Koren G**: Discordance between physical symptoms versus perception of severity by women with nausea and vomiting in pregnancy. (NVP). *BMC Pregnancy Childbirth.* 2: 5 (2002).

Von Dadelszen P, Magee LA, Lee SK, Stewart SD, Simone C, **Koren G**, Walley KR, Russell JA: Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity? *Crit Care Med.* 30:1883-92 (2002).

Till C, **Koren G**, Rovet JF: Agreement between prospective and retrospective reports of maternal exposure to chemicals during pregnancy. *J Occup Environ Med.* 44: 708-13 (2002).

Kozer E, Scolnik D, Macpherson A, Keays T, Shi K, Luk T, **Koren G**: Variable associated with medication errors in pediatric emergency medicine. *Pediatrics* 110: 737-42 (2002).

Geshundheit B, Kirby M, Lau W, **Koren G**, Abdelhaleem M: Thrombocytopenia and megakaryocyte dysplasia: an adverse effect of valproic acid treatment. *J Pediatr Hematol Oncol.* 24: 589-90 (2002).

Goldman RD, **Koren G**: Biologic markers of pain in the vulnerable infant. *Clin Perinatol.* 29: 415-25 (2002).

Forman R, **Koren G**, Shear NH: Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. *Drug Safety* 25: 965-72 (2002).

Kagan-Kreiger S, Selby P, Vohra S, **Koren G**: Paternal alcohol exposure and turner syndrome. *Alcohol*. 37: 613-7 (2002).

Costei AM, Kozer E, Ho T, Ito S, **Koren G**: Perinatal outcome following third trimester exposure to paroxetine. *Arch Pediatr Adolesc Med*. 156:1129-32 (2002).

Klein J, Chan D, **Koren G**: Neonatal hair analysis as a biomarker for in utero alcohol exposure. *N Engl J Med*. 347: 2086 (2002).

Kozer E, Scolnik D, Keays T, Shi K, Luk T, **Koren G**: Large errors in the dosing of medications for children. *Op cit* 346:1175-6 (2002).

Stempak D, Gammon J, Klein J, **Koren G**, Baruchel S: Single-dose and steady state pharmacokinetics of celecoxib in children. *Clin Pharmacol Ther*. 72: 490-7 (2002).

---

## "L"

**Lanctôt KL**, Herrmann N, van Reekum R, Eryavec G, Naranjo CA: Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. *Int J Ger Psychiatry* 17:531-41 (2002).

Schaffer A, Levitt AJ, Hershkop SK, Oh P, MacDonald C, **Lanctôt KL**: Utility scores of symptom profiles in major depression. *Psychiatry Res* 110:189-197 (2002).

Oh PI, **Lanctôt KL**, Yoon A, Lee DSC, Paes BA, Simmons BS, Parison D, Manzi P, on behalf of the COMPOSS Investigators: Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. *Pediatric Infect Dis J* 21(6):512-8 (2002).

Paradiso-Hardy FL, Papastergiou J, **Lanctôt KL**, Cohen EA: Thrombotic thrombocytopenic purpura associated with clopidogrel: Further evaluation. *Can J Cardiol*. 18:771-3 (2002).

**Lanctôt KL**, Herrmann N, Eryavec G, van Reekum R, Reed K, Naranjo CA: Central serotonergic activity is related to the aggressive behaviours of Alzheimer's disease. *Neuropsychopharmacology* 27: 647-655 (2002).

Optenberg SA, **Lanctôt KL**, Herrmann N, Oh PI: Antidepressant selection, healthcare resource consumption and costs in a large workplace environment - U.S. and Canadian perspectives. *Clin Drug Invest*. 22(10): 685-94 (2002).



Dergal JM, Gold JL, Laxer DA, Lee MSW, Binns MA, **Lanctôt KL**, Freedman M, Rochon PA: Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. *Drugs Aging* 19:879-86 (2002).

---

**Lê AD**: Effects of nicotine on alcohol consumption. *Alcohol Clin Exp Res.* 26:1915-6 (2002).

McBride W, **Lê AD**, Noronha A: Central nervous system mechanisms in alcohol relapse. *Alcohol Clin Exp Res.* 26:280-6 (2002).

**Lê AD**, Harding S, Juzysch W, Fletcher PJ, Shaham Y: The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol. *J Neurosci.* 22:7844-9 (2002).

**Lê AD**, Shaham Y: Neurobiology of relapse to alcohol in rats. *Pharmacol Ther.* 94:137-56 (2002).

---

## "M"

Yeung JY, Canning KJ, Zhu G, Pennefather P, **MacDonald JF**, Orser BA: Tonicly activated GABAA receptors in hippocampal neurons are high-affinity, low-conductance sensors for extracellular GABA. *Mol Pharmacol* 63: 2-8 (2002).

Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, Van Tol HM, **MacDonald JF**: A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. *Neuron.* 35: 1-20 (2002).

Meng Y, Zhang Y, Tregoubov V, Janus, C, Cruz L, Jackson M, Lu WY, **MacDonald JF**, Wang JY, Falls DL, Jia Z: Abnormal spine morphology and enhanced LTP in LIMK-1 knockout mice. *Neuron.* 35: 121-33 (2002).

Caraiscos VB, Mihic SJ, **MacDonald JF**, Orser BA: Tyrosine kinases enhance the function of glycine receptors in rat hippocampal neurons and human alpha(1)beta glycine receptors. *J Physiol.* 539: 495-502 (2002).

Kotecha SA, **MacDonald JF**: Signaling molecules and receptor transduction cascades that regulate NMDA receptor-mediated synaptic transmission. *Int Rev Neurobiol* vol 54, (2002).

---

Head E, Liu J, Hagen TM, Muggenburg BA, **Milgram NW**, Ames BN, Cotman CW: Oxidative damage increases with age and  $\beta$ -amyloid deposition in a canine model of human brain aging. *J Neurochem* 82: 375-81 (2002).

Chan, ADF, Nippak P, Murphey H, Ikeda-Douglas C, Muggenberg B, Head E, Cotman CW, **Milgram NW**: Visuospatial Impairments in Aged Canines: The Role of Cognitive-Behavioral Flexibility. *Behav Neurosci* 116: 443-54 (2002).

Siwak CT, Murphey HL, Muggenberg BA, **Milgram NW**: Age-Dependent Decline in Locomotor Activity in Dogs is Environment Specific. *Physiol and Behav* 75: 65-70 (2002).

**Milgram NW**, Zicker E, Head BA, Muggenberg H, Murphey C, Ikeda-Douglas, Cotman CW: Dietary enrichment counteracts age-associated cognitive dysfunction in canines. *Neurobiol Aging* 23: 805 (2002).

Cotman CW, Head E, Bruce A, Muggenberg S, Zicker and **Milgram NW**: Brain Aging in the Canine: A Diet Enriched in Antioxidants Reduces Cognitive Dysfunction. *Neurobiol Aging* 23: 737 (2002).

**Milgram NW**, Head E, Muggenberg B, Holowachuk D, Murphey H, Estrada CJ, Ikeda-Douglas S C, Zicker and C.W. Cotman: Landmark discrimination learning in the dog: effects of age, an antioxidant fortified diet, and cognitive Strategy. *Neurosci Biobehav Rev* 26: 679-95 (2002).

---

Cheung R, Kassirian S, **Mitchell J**: Diurnal regulation of the G protein G11a and guanine nucleotide-regulated phospholipase C activity in rat retina. *Exp Eye Res.* 75: 371-374 (2002).

Cheung R, **Mitchell J**: Mechanisms of regulation of G11a protein by dexamethasone in osteoblastic UMR-106-01 cells. *Am J Physiol.* 282: E24-E30 (2002).

Erclik M, **Mitchell J**: The role of protein kinase C-d in parathyroid hormone stimulation of IGF-binding protein-5 mRNA expression in UMR-106-01 cells. *Am J Physiol.* 282: E534-E541 (2002).

---

**Mittmann N**, Jivraj F, Wong A, Yoon A. Meta-analysis of oral fluoroquinolones in the treatment of community-acquired pneumonia and acute exacerbations of chronic bronchitis. *Can J Infect Dis* 13: 293-300 (2002).

Iskedjian M, Einarson TR, MacKeigan LD, Shear NH, Addis A, **Mittmann N**, Ilersich AL. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis. *Clin Therap* 24:302-316 (2002).

---

Chung P, Parker C, Panzarella T, Gospodarowicz MK, Jewett MAS, Milosevic M, Catton CN, Bayley AJ, Tew B, **Moore MJ**, Sturgeon JFG, Warde P: Surveillance in stage I testicular seminoma B risk of late relapse. *Can J Urol.* 9: 1637-1640 (2002.).

Juffs HG, **Moore MJ**, Tannock IF: The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. *Lancet Oncology* 3: 738-747 (2002).

Belanger K, **Moore MJ**, Baker S, Dionne J, Maclean M, Jolivet J, Siu L, Soulieres D, Wainman N, Seymour L: Phase I and pharmacokinetic study of a novel L-nucleoside troxacitabine given as a 30 minute infusion every 21 days. *J Clin Oncol.* 20:2567-2574 (2002).

**Moore MJ**: Pancreatic cancer: what the oncologist can offer for palliation. *Can J Gastroenterol.* 16:121-4 (2002).

Stadler WM, Hayden A, von der Maase H, Roychowdry D, Dogliotti L, Donald Kaufmann D, **Moore MJ**: Long Term survival in patients treated with gemcitabine plus cisplatin for advanced transitional cell cancer. *Urol Oncol.* 7:153-7 (2002).

Tolcher AW, Reyno L, Venner PM, Ernst SD, **Moore MJ**, Geary RS, Chi K, Hall S, Walsh W, Dorr, A, Eisenhauer E: A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone refractory prostate cancer. *Clin Cancer Res.* 8:2530-2535 (2002).

Michael M, Hedley D, Oza A, Feld R, Pintilie M, Goel R, Maroun J, Jolivet J, Fields A, Lee IM, **Moore MJ**: The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. *Clin Colorectal Cancer* 2: 93-101 (2002).

---

## "N"

Tremblay LK, **Naranjo CA**, Cardenas L, Herrmann N, Busto UE: Probing the brain reward system in major depressive disorder: Altered response to d-amphetamine. *Archives of General Psychiatry* 59: 409-416 (2002).

Lancot KL, Herrmann N, van Reekum R, Eryavec G, **Naranjo CA**: Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. *Int J Ger Psychiatry* 17: 531-541 (2002).

**Naranjo CA**, Chu AY, Tremblay LK: Neurodevelopmental liabilities in alcohol dependence; central serotonin and dopamine dysfunction. *Neurotox Res* 4: 343-361 (2002).

Lancot KL, Herrmann N, Eryavec G, van Reekum R, Reed K, **Naranjo CA**: Central serotonergic activity is related to the aggressive behaviours of Alzheimer's disease. *Am J Psychiatry* 27: 646-654 (2002).

Cardenas L, Tremblay LK, **Naranjo CA**, Herrmann N, Zack M, Busto UE. Brain reward system activity in major depression and comorbid nicotine dependence. *J Pharmacol Exp Therap* 302: 1265-1271 (2002).

Sproule BA, **Naranjo CA**, Turksen IB. Fuzzy pharmacology: Theory and applications. *Trends in Pharmacological Sciences* 23: 412-417 (2002).

Kilic K, Sproule BA, Turksen IB, **Naranjo CA**. Fuzzy system modeling in pharmacology. An improved algorithm. *Fuzzy Sets and Systems* 130: 253-264 (2002).

---

**Neuman MG**, Benhamou JP, Bourliere M, Ibrahim A, Malkiewicz I, Asselah T, Martinot-Peignoux M, Shear NH, Katz GG, Akremi R, Benali S, Boyer N, Lecomte L, Le Breton V, Le Guludec G, Marcellin P: Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis c patients are immunomodulated by therapy. *Cytokine*. 17:108-117 (2002).

**Neuman M**, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, Haber J, Katz G, Lindor K: Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. *J Gastroenterol Hepatol*. 17:196-202 (2002).

Popat A, Shear NH, Malkiewicz I, Thomson S, **Neuman MG**: Mechanism of Impila (*Callilepis laureola*)-induced cytotoxicity in Hep G2 cells. *Clin Biochem*. 35:57-64 (2002).

**Neuman MG**, Benhamou JP, Malkiewicz IM, Ibrahim A, Valla DC, Martinot-Peignoux M, Asselah T, Bourliere M, Katz GG, Shear NH, Marcellin P: Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. *J Viral Hepatitis* 9:134-40 (2002).

**Neuman MG**: Apoptosis in liver disease. *Rom J Gastroenterol*. 11: 3-7 (2002).

**Neuman MG**, Haber JA, Malkiewicz IM, Cameron RG, Katz GG, Shear NH: Ethanol signals for apoptosis in cultured skin cells. *Alcohol* 26:179-90 (2002).

**Neuman MG**, Thompson S, Malkiewicz IM, Popat A, Shear NH: Response to the editor for Mechanism of Impila (*Callilepis laureola*)-induced cytotoxicity in Hep G2 cells. *Clin Biochem*. 35:179-80 (2002).

**Neuman MG**, Cameron RG, Haber JA, Katz GG, Blendis LM: An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis. *Liver* 22: 235-244 (2002).

Molina P, Diehl AM, Guidot A, McClain C, Valla DC, Lang C, **Neuman MG**: Molecular Pathology and Clinical Aspects of Alcohol-Induced Tissue Injury. *Alcoholism: Clin Exp Res* 26: 120-128 (2002).

**Neuman MG**, Benhamou JP, Ibrahim A, Malkiewicz IM, Spiricu T, Martinot-Peignoux M, Shear NH, Katz GG, Akremi R, Bourliere M, Marcellin P: Role of cytokines in the assessment of the

severity of chronic hepatitis C and the prediction of response to therapy. *Rom J Gastroenterol.* 11: 97-103 (2002).

**Neuman MG:** Synergetic signaling for apoptosis in vitro by ethanol and acetaminophen. *Alcohol.* 27: 89-98 (2002).

**Neuman MG,** Gady Katz, Izabella Malkiewicz , Philippe Mathurin, Hide Tsukamoto Masayuki Adachi, Hiromasa Ishii, Anna Colell, Carmen García-Ruiz, José C. Fernández-Checa, Carol A: Casey. Alcoholic liver injury and apoptosis: synopsis of the symposium held at ESBRA 2001: 8th Congr Eur Soc Biomed Res on Alcoholism, Paris, September 16, 2001, *Alcohol,* 27: 102-112 (2002)

Ibrahim A, Katz GG, **Neuman MG:** Tumor necrosis factor alpha as a non-invasive marker of liver inflammation in patients with viral hepatitis C. Viral hepatitis series. *Am Clin Lab,* 1002-1005 (2002).

Ibrahim A, **Neuman MG:** Cytokines in viral hepatitis C, role of treatment. *Rev Rom Hepatol,* 2: 5-9 (2002)

**Neuman MG,** Benhamou JP, Malkiewicz IM, Ibrahim A, Valla DC, Martinot-Peignoux M, Asselah T, Spircu T, Bourliere M, Katz GG, Shear NH, Marcellin P: Serum tumor necrosis factor levels in chronic hepatitis C. *Rom J Gastroenterol.* 11: 5-17 (2002).

**Neuman MG,** Malkiewicz IM, Phillips EJ, Ong D, Neilson H, Yeung E, Rachlis A, Shear NH: A novel lymphocyte toxicity test for hypersensitivity syndrome in HIV-infected individuals. *Therap Drug Monit* 24: 4 (2002).

**Neuman MG:** Immunomodulatory effects of ursodeoxycholate treatment in primary biliary cirrhosis and primary sclerosing cholangitis. In: Paumgartner G, Stiehl A, Leuschner U, (eds.). Bile Acids in Cholestasis. Ch 33. Lancaster UK: Kluwer Acad Publ, 2002, Ch 33. 294-309.

---

Hipólide DC, D'Almeida V, Raymond R, Tufik S, **Nobrega JN:** Sleep deprivation does not affect indices of gliosis or apoptosis in rat brain. *Int J Neurosci* 112: 155-166 (2002).

Quadros IMH, Hipólide DC, Frussa-Filho R, de Lucca EM, **Nobrega JN,** Souza-Formigoni MLO: Resistance to ethanol sensitization is associated with increased levels of NMDA receptor binding in specific brain areas. *Eur J Pharmacol* 442: 55-61 (2002).

Quadros IMH, Souza-Formigoni MLO, de Lucca EM, Hipólide DC, **Nobrega JN:** Differential propensity to behavioral sensitization to ethanol is not associated with altered dopamine transporter or D1 receptor binding in mice. *Addiction Biology* 7: 291-299 (2002).

**Nobrega JN**, Raymond R, Barlow K, Löscher W, Richter A: Changes in AMPA receptor binding in an animal model of inborn paroxysmal dystonia. *Exp Neurology* 176: 371-376 (2002).

Turrone P, Remington G, **Nobrega JN**: The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy? *Neurosci Biobehav Rev* 26: 361-380 (2002).

Friedman Y, Richter A, Raymond R, Löscher W, **Nobrega JN**: Regional decreases in NK-3, but not NK-1 tachykinin receptor binding in dystonic hamster (dtsz) brains. *Neuroscience* 112: 639-645 (2002).

Kapur S, McClelland RA, VanderSpek SC, Wadenberg ML, Baker G, **Nobrega JN**, Zipursky R, Seeman P: Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. *Neuroreport* 13: 831-835 (2002).

de Oliveira AC, d'Almeida V, Hipólido DC, **Nobrega JN**, Tufik S: Sleep deprivation reduces total plasma homocysteine levels in rats. *Can J Physiol Pharmacol* 80: 193-197 (2002).

Wunderlich GR, Raymond R, DeSousa NJ, **Nobrega JN**, Vaccarino FJ: Decreased CCKb receptor binding in rat amygdala in animals demonstrating greater anxiety-like behavior. *Psychopharmacology* 164: 193-199 (2002).

---

**"O"**

Galati G, Tafazoli S, Sabzevari O, Chan TS, **O'Brien PJ**: Idiosyncratic NSAID drug induced oxidative stress. *Chem-Biol Interact.* 142: 25-41 (2002).

Moridani MY, Cheon SS, Khan S, O'Brien, PJ: Metabolic activation of 4-hydroxyanisole by isolated rat hepatocytes. *Drug Metab Dispos.* 30: 1063-1069 (2002).

Siraki, AG, Chan TS, Galati G., Teng S, **O'Brien PJ**: N-oxidation of aromatic amines by intracellular oxidases. *Drug Metab Rev.* 34: 549-564 (2002).

Galati G, Sabzevari O, Wilson JX, **O'Brien PJ**: Prooxidant activity and cellular effects of the phenoxy radicals of dietary flavonoids and other polyphenolics. *Toxicology* 177: 91-104 (2002).

Siraki AG, **O'Brien PJ**: Prooxidant activity of free radicals derived from phenol-containing neurotransmitters. *Toxicology* 177: 81-90 (2002).

Moridani MY, Scobie H, **O'Brien PJ**: Metabolism of caffeic acid by isolated rat hepatocytes and subcellular fractions. *Toxicol Lett.* 133: 141-151 (2002).

Chan, TS, Teng S, Wilson JX, Galati G, Khan S, **O'Brien PJ**: Coenzyme Q cytoprotective mechanisms for mitochondrial complex I cytopathies involves NAD(P)H: quinone oxidoreductase 1(NQO1). *Free Radic Res.* 36: 421-427 (2002).

Moridani MY, Galati G, **O'Brien PJ**: Comparative quantitative structure toxicity relationships for flavonoids evaluated in isolated rat hepatocytes and HeLa tumor cells. *Chem-Biol Interact.* 139: 251-264 (2002).

Siraki AG, Pourahmad J, Chan TS, Khan S, **O'Brien PJ**: Endogenous and endobiotic induced reactive oxygen species formation by isolated hepatocytes. *Free Radic Biol Med.* 32: 2-10 (2002).

---

Croston GE, Olsson R, Currier EA, Burstein ES, Weiner D, Nash N, Severance D, Allenmark SG, Thunberg L, Ma JN, Mohell N, **O'Dowd BF**, Brann MR, Hacksell U: Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2-ethyl)isochroman-1-one (AC-7954). *J Med Chem* 45: 4950-4953 (2002).

Lamey M, Thompson M, Varghese G, Chi H, Sawzdargo M, George SR, **O'Dowd BF**: Distinct residues in the carboxyl tail mediate agonist-induced desensitization and internalization of the human dopamine D-1 receptor. *J Biol Chem* 277: 9415-9421 (2002).

Levac BAR, **O'Dowd BF**, George SR: Oligomerization of opioid receptors: generation of novel signaling units. *Curr Opin Pharmacol* 2: 76-81 (2002).

Lee DK, George SR, **O'Dowd BF**: Novel G protein-coupled receptor genes expressed in the brain: Continued discovery of important therapeutic targets. *Expert Opinion in Therapeutic Targets* 6: 185-202, (2002).

George SR, **O'Dowd BF**, Lee SR: G-protein-coupled receptor oligomerization and its potential for drug discovery. *Nature Reviews Drug Discovery* 1: 808-820 (2002).

Demchyshyn LL, **O'Dowd BF**, George SR: Structure of mammalian D1 and D5 dopamine receptors and their function and regulation in cells. In: Sidhu A, Laruelle M, Vernier P, (eds). Dopamine Receptors and Transporters. Marcel Dekker, New York, 2002.

---

McAllister FA, Zarnke KB, Campbell NR, **Ogilvie RI** et al. The 2001 Recommendations for the treatment of hypertension. Part 2 : Therapy. *Can J Cardiology* 18: 625-41 (2002).

---

Ozdemir V, Kalow W, **Okey AB**, Lam MSM, Albers LJ, Reist C, Fourie J, Posner P, Collins EJ: Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the



C-Apolymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. *J Clin Psychopharmacology* (2002).

SY, SKB, Ciaccia A, Li W, Roberts EA, **Okey AB**, Tang BK & Kalow W. Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates bimodal distribution in CYP3A4 gene expression. *Eur J Clin Pharmacol* 58:357-365 (2002).

Harper PA, Wong JMY, Lam MSM & **Okey AB**: Polymorphisms in the human AH receptor. *Chem-Biol Interactions* 141:161-187 (2002).

---

## "P,Q"

Jankov RP, Luo XP, Demin P, Aslam R, Hannam V, Tanswell AK, **Pace-Asciak CR**: Hepoxilin analogs inhibit bleomycin-induced pulmonary fibrosis in the mouse. *J Pharmacol Exp Ther* 301: 435-440 (2002).

**Pace-Asciak CR**, Reynaud D, Demin P, Aslam R, Sun A: A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition. *J Pharmacol Exp Ther* 301: 618-624 (2002).

Reynaud D, Hinek A, **Pace-Asciak CR**: The hepoxilin analog, PBT-3, inhibits heparin-activated platelet aggregation evoked by ADP. *FEBS Lett.* 515: 58-60 (2002).

---

Meng L-J, Wang PJ, Wolkoff AW, Kim RB, Tirona RG, Hofmann AF, **Pang KS**: Transport of sulfolithocholytaurine into isolated rat hepatocytes is mediated by Oatp1 and Oatp2. *Hepatology* 35: 1031-1040 (2002).

---

Notarius CF, Azevedo ER, **Parker JD**, Floras JS: Peak oxygen uptake is not determined by cardiac noradrenaline spillover in heart failure. *Eur Heart J* 23: 800-805 (2002).

Lorenzi-Filho G, Azevedo ER, **Parker JD**, Bradley TD: Relationship of carbon Dioxide tension in arterial blood to pulmonary wedge pressure in heart. *Eur Respir J.* 19: 37- 40 (2002).

Al-Hesayen A, Azevedo ER, Newton GE, **Parker JD**: The effects of dobutamine on cardiac sympathetic activity inpatients with congestive heart failure. *J Am Coll Cardiol* 1739:1269-74 (2002).

---



Baker PM, **Pennefather PS**, Orser BA, Skinner FK: Effect of anesthetic induced potentiation on GABA<sub>A</sub> receptors on oscillations in interneuron network. *J Neurophysiology* 88: 2821-2833 (2002).

---

## "R"

Timsit YE, **Riddick DS**: Stimulation of hepatic signal transducer and activator of transcription 5b by GH is not altered by 3-methylcholanthrene. *Endocrinology* 143: 3284-3294 (2002).

Bhathena A, Lee C, **Riddick DS**: Suppression of cytochrome P450 2C11 by aromatic hydrocarbons: mechanistic insights from studies of the 5'-flanking region of the CYP2C11 gene. *Drug Metab Dispos.* 30: 1385-1392 (2002).

Timsit YE, Chia FSC, Bhathena A, **Riddick DS**: Aromatic hydrocarbon receptor expression and function in liver of hypophysectomized male rats. *Toxicol Appl Pharmacol.* 185: 136-145 (2002).

---

McCloskey P, Tottle R, Selden C, Larsen F, **Roberts EA**, Hodgson HJF: Modulation of hepatocyte function in an immortalized human hepatocyte line following exposure to liver failure plasma. *Artif Organs* 26: 340-348 (2002).

Ayers M, Siu K, **Roberts E**, Garvin AM, Tellier R: Characterization of hepatitis C virus quasispecies by MALDI-TOF mass spectrometry mutation detection. *J Clin Microbiol.* 40: 3455-3462 (2002).

Sy SKB, Ciaccia A, Li W, **Roberts EA**, Okey A, Kalow W, Tang BK: Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. *Eur J Clin Pharmacol.* 58: 357-365 (2002).

Yeung LTF, Petric M, Cutz E, **Roberts EA**: Histological improvement with lamivudine therapy for de novo hepatitis B occurring in an anti-HBs-positive child after bone marrow transplantation. *Bone Marrow Transplantation* 30: 459-462 (2002).

**Roberts EA**, Yeung LTF: Maternal-infant transmission of hepatitis C virus infection. *Hepatology* 36( Suppl):S106-13 (2002).

**Roberts EA**: Steatohepatitis in children. *Baillière's Best Prac Res Clin Gastroenterol* 16: 749-65 (2002).

Sy SKB, **Roberts EA**, Kalow W, Tang BK: Multivariate cluster analysis of human hepatic cytochromes P450. *Eur J Clin Pharmacol.* 58: 559-562 (2002).

**Roberts EA:** Progressive familial intrahepatic cholestasis. In: Jonas M, (ed). Rudolph's Pediatrics, 21st edition. Liver Disease section. pp. 1493-1495 (2002).

**Roberts EA:** Wilson's disease. In Chapman R, Gilmore I, (eds.). Medicine (Liver II), Oxford, UK, 30: 65-55 (2002).

---

**Rozmahel R,** Huang J, Chen F, Liang Y, Nguyen V, Ikeda M, Levesque G, Yu G, Nishimura M, Mathews P, Schmidt S, Mercken M, Bergeron C, Westaway D, St George-Hyslop P: Normal brain development in PS1-hypomorphic mice with markedly reduced  $\gamma$ -secretase cleavage of  $\beta$ APP. *Neurobiol Aging* 23; 187-194 (2002).

Haston CK, McKerlie C, Newbigging S, Corey M, **Rozmahel R,** Tsui L-C: Detection of Modifier Loci Influencing the Lung Phenotype of Cystic Fibrosis Knockout Mice. *Mammalian Genome* 13(11); 605-613 (2002).

**Rozmahel R,** Mount HTJ, Chen F, Nguyen V, Huang J, Erdebil S, Liauw J, Yu G, Hasegawa H, Gu Y.J, Song Y-Q, Schmidt SD, Nixon RA, Mathews PM, Bergeron C, Fraser P, Westaway D, St George-Hyslop P: Alleles at the Nicastrin Locus Modify Presenilin 1 Deficiency Phenotype. *Proc Natl Acad Sci* 99: 14452-14457 (2002).

Liauw JA, Huang J, Nguyen V, **Rozmahel R:** Differential display analysis of presenilin 1-deficient mouse brains. *Mol Brain Res* 109: 56-62 (2002).

---

## "S"

Parker KL, Rice DA, Lala DS, Ikeda Y, Luo X, Wong M, Bakke M, Zhao L, Frigeri C, Hanley NA, Stallings N, **Schimmer BP:** Steroidogenic Factor 1: an Essential Mediator of Endocrine Development. *Rec Prog Hormone Res.* 57: 19-36 (2002).

Frigeri C, Tsao J, Cordova M, **Schimmer BP:** A polymorphic form of steroidogenic factor-1 is associated with ACTH resistance in Y1 mouse adrenocortical tumor cell mutants. *Endocrinology* 143: 4031-4037 (2002).

Parker KL, Schimmer BP: Genes essential for early events in gonadal development. *Ann Med.* 34: 171-178 (2002).

**Schimmer BP,** Cordova M, Tsao J, Frigeri C: SF1 polymorphisms in the mouse and steroidogenic potential. *Endocr Res.* 28: 519-525 (2002).

Parker KL, **Schimmer BP:** Genetics of sex determination. In: Baxter JD, Melmed S, New MI (eds.). Genetics in Endocrinology. vol. 10 ed. Philadelphia, Lippincott Williams & Wilkens, pp. 365-374 (2002).

---

**Seeman P**, Madras BK: Methylphenidate elevates resting dopamine which lowers impulse-triggered release of dopamine: a hypothesis. *Behav Brain Res.* 130: 79-83 (2002).

**Seeman P**: Atypical Antipsychotics: Mechanism of Action. *Can J Psychiatry.* 47: 27-38 (2002).

Novak G, Kim D, Seeman P, Tallerico T: Schizophrenia and Nogo: elevated mRNA in frontal cortex and higher prevalence of a homozygous CAA insert polymorphism. *Mol Brain Res.* 107: 183-189 (2002).

Kapur S, **Seeman P**: Atypical antipsychotics, cortical D2 receptors and sensitivity to endogenous dopamine. *Brit J Psychiatry.* 180: 465-466 (2002)

Ko F, **Seeman P**, Sun WS, Kapur S: Dopamine D2 receptors internalize in their low-affinity state. *Neuroreport* 13: 1017-1020 (2002).

**Seeman P**, Tallerico T, Ko F, Tenn C, Kapur S: Amphetamine-sensitized animals show a marked increase in dopamine D2High receptors occupied by endogenous dopamine, even in the absence of acute challenges. *Synapse* 46: 235-239 (2002).

Seeman MV, **Seeman P**: Choosing an antipsychotic and why. *Medscape* (2002).

Kapur S, McClelland RA, VanderSpek SC, Wadenberg ML, Baker G, Nobrega J, Zipursky RB, **Seeman P**: Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. *Neuroreport* 13(6): 831-5 (2002).

---

Xu C, Rao YS, Xu B, Hoffmann E, Jones J, **Sellers EM**, Tyndale RF: An in vivo pilot study characterizing the new CYP2A6\*7, \*8 and \*10 alleles. *Biochem Biophys Res Comm.* 290: 318-324 (2002).

Zhang W, Kilicarslan T, Ramamoorthy Y, Nolte H, Tyndale RF, **Sellers EM**: Inhibition of cytochrome P450s by antifungal imidazole derivatives. *Drug Metab Dispos.* 30: 314-318 (2002).

Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, **Sellers EM**, Romach MK: Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. *J Clin Psychopharmacol.* 22: 326-329 (2002).

Pritzker D, Kanungo A, Kilicarslan T, Tyndale RF, **Sellers EM**: Designer drugs that are potent inhibitors of CYP2D6. *J Clin Psychopharmacol.* 22: 330-332 (2002).

Tyndale RF, **Sellers EM**: Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. *Ther Drug Mon.* 24: 163-171 (2002).

Howard LA, **Sellers EM**, Tyndale RF: The role of pharmacogenetics in drug abuse and dependence. *Pharmacogenomics* 3: 185-199 (2002).

Zhang W, Tyndale RF, Glick SD, Maisonneuve IM, Kuehne ME, **Sellers EM**: Metabolism of 18-methoxycoronaridine, an ibogaine analogue, to 18-hydroxycoronaridine by genetically variable CYP2C19. *Drug Metab Dispos.* 30: 663-669 (2002).

Zeman MV, Hiraki L, Tyndale RF, **Sellers EM**: Gender differences in tobacco smoking: Higher relative exposure to smoke than nicotine in women. *J Women's Health Gender-Based Med.* 11: 147-153 (2002).

Ramamoorthy Y, Yu A-M, Shu N, Haining RL, Tyndale RF, **Sellers EM**: Reduced ("3,4-methylenedioxy-methamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. *Biochem Pharmacol.* 63: 2111-2119 (2002).

Kim M-J, Bertino JS., Gaedigk A, Zhang Y, **Sellers EM**, Nafziger AN: Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. *Clin Pharmacol Ther.* 72: 192-199 (2002).

Xu C, Goodz S, **Sellers EM**, Tyndale RF: CYP2A6 genetic variation and potential consequences. *Advanced Drug Delivery Rev* 54: 1245-1256 (2002).

Romach MK, **Sellers EM**, Somer GR, Landry M, Cunningham GM, Jovey RD, McKay C, Boislard J, Mercier C, Pépin J-M, Perreault J, Lemire É, Baker RP, Campbell W, Ryan D: Naltrexone in the treatment of alcohol dependenceCA Canadian trial. *Can J Clin Pharmacol.* 9: 130-136 (2002).

Miksys S, Rao Y, Hoffmann E, **Sellers EM**, Mash DM, Tyndale RF: Regional and cellular expression of cytochrome P450 2D6 in human brain: Higher levels in alcoholics. *J Neurochem* 82: 1-12 (2002)

---

**Semple JW**, Allen D, Rutherford M, Wakefield C, David M, Freedman J, Woloski M, Butchart S, Blanchette V: Anti-D (WinRho SDTM) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. *Amer J Hematol.* 69:225-227 (2002).

**Semple JW**, Kim M, Lazarus AH and Freedman J: Gammaglobulins prepared from the sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response. *Blood* 100:1055-1059 (2002).

**Semple JW**: Immune physiology of autoimmune thrombocytopenic purpura. **Blood Rev.** 16:9-12 (2002).

**Semple JW**, Freedman J: Recipient antigen processing pathways of allogeneic platelet antigens: essential mediators of immunity. *Transfusion* 42:958-961 (2002), (Cover).

**Semple JW**, Freedman J: Leukoreduction just doesn't "take away" immunogenic leukocytes, it creates an immunosuppressive leukocyte dose. *Vox Sanguinis* 83: 425-427 (2002).

**Semple JW**: The role of NO in modulating platelet alloimmunity. In: The Compendium. AABB Press, Bethesda MD, 2002 pp 154-155.

---

Rivers JK, Arlette J, **Shear NH**, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. *Br J Dermatol.* 146: 94-100 (2002),

Neuman MG, Benhamou JP, Malkiewicz IM, Ibrahim A, Valla DC, Martinot-Peignoux M, Asselah T, Bourliere M, Katz GG, **Shear NH**, Marcellin P: Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. *J Viral Hepat.* 9: 134-140 (2002).

Iskedjian M, Einarson TR, MacKeigan LD, **Shear NH**, Addis A, Mittmann N, Ilersich AL: Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis. *Clin Therap* 24: 302-316 (2002).

Atkinson NF Jr, Essayan D, Gruchalla R, Haggerty H, Kawabata T, Sandler D, Updyke L, **Shear NH**, Wierda D: Task Force Report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. *J Allergy Clin Immunol.* 109: S461-78 (2002).

Neuman MG, Haber JA, Malkiewicz IM, Cameron RG, Katz GG, **Shear NH**: Ethanol signals for apoptosis in cultured skin cells. *Alcohol* 26: 179-190 (2002).

Shapiro LE, **Shear NH**: Drug interactions and the dermatologist: proteins, pumps and P450s. *J Am Acad Dermatol.* 47: 467-84 (2002).

Phillips EJ, Sullivan JR, Knowles SR, **Shear NH**: Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. *AIDS* 16: 2223-5 (2002).

Foreman R, Koren G, **Shear NH**: Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. *Drug Safety* 25: 965-72 (2002).

Neuman MG, Benhamou JP, Bourliere M, Ibrahim A, Malkiewicz I, Asselah T, Martinot-Peignoux M, **Shear NH**, Katz GG, Akremi R, Benali S, Boyer N, Lecomte L, Le Breton V, Le Guludec G, Marcellin P: Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis c patients are immunomodulated by therapy. *Cytokine.* 17:108-17 (2002).

Neuman M, Angulo P, Malkiewicz I, Jorgensen R, **Shear N**, Dickson ER, Haber J, Katz G, Lindor K: Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. *J Gastroenterol Hepatol.* 17:196-202 (2002).

Popat A, **Shear NH**, Malkiewicz I, Thomson S, Neuman MG: Mechanism of Impila (*Callilepis laureola*)-induced cytotoxicity in Hep G2 cells. *Clin Biochem.* 35:57-64 (2002).

Neuman MG, Benhamou JP, Malkiewicz IM, Ibrahim A, Valla DC, Martinot-Peignoux M, Asselah T, Spiricu T, Bourliere M, Katz GG, **Shear NH**, Marcellin P: Serum tumor necrosis factor levels in chronic hepatitis C. *Rom J Gastroenterol.* 11: 5-17 (2002).

Neuman MG, Malkiewicz IM, Phillips EJ, Ong D, Neilson H, Yeung E, Rachlis A, **Shear NH**: A novel lymphocyte toxicity test for hypersensitivity syndrome in HIV-infected individuals. *Therap Drug Monit* 24: 4 (2002).

---

Cortez MA, Ryan MA, Cunnane SC, **Snead OC**: Brain Sterols In The AY-9944 Rat Model Of Atypical Absence Seizures. *Epilepsia* 43: 3-8 (2002).

Persad V, Cortez MA, **Snead OC**: A Chronic Model Of Atypical Absence Seizures: Studies Of Developmental And Gender Sensitivity. *Epilepsy Res* 48:111-119 (2002).

Gibson KM, Schor DSM, Gupta M, Guerand WS, Senephansiri H, Burlingame TG, Bartels H, Hogema BM, Bottiglieri T, Froestl W, **Snead OC**, Grompe M, Jakobs C: Focal Neurometabolic Alterations In Mice Deficient For Succinate Semialdehyde Dehydrogenase. *J Neurochem* 81: 71-79 (2002).

Gupta M, Greven R, Jansen EE, Jakobs C, Hogema BM, Froestl W, **Snead OC**, Bartels H, Gibson KM: Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). *J Pharmacol Exp Ther* 302:180-187 (2002).

Mackay M, Weiss S, **Snead OC**: Treatment Of Infantile Spasms: An Evidence-Based Approach. *Int Rev Neurobiol.* 49:157-184 (2002).

Ochi A, Otsubo H, Honda Y, Hara Y, Sharma R, Elliott I, Rutka JT, Chuang SH, Kamijo K, Kiyuna T, Yamazaki T, **Snead OC**: Electroencephalographic Dipoles Of Spikes With And Without Myoclonic Jerks Caused By Epilepsia Partialis Continua. *J Child Neurol.* 17:127-131 (2002).

Akai T, Otsubo H, Pang EW, Rutka JT, Chitoku S, Weiss SK, **Snead OC**: Complex central cortex in pediatric patients with malformations of cortical development. *J Child Neurol.* 17:347-352 (2002).

Chen LS, Otsubo H, Ochi A, Lai WW, Sutoyo D, **Snead OC**: Continuous potential display of ictal electrocorticography. *J Clin Neurophysiol* 19:192-203 (2002).

---

## "T"

Sy SKB, Ciaccia A, Li W, Roberts EA, Okey A, Kalow W, **Tang BK**: Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. *Eur J Clin Pharmacol* 58: 357-365 (2002).

Sy SKB, **Tang BK**, Johnston JA, Roberts EA, Kalow W: Multivariate cluster analysis of a human hepatic cytochrome P450 database. *Eur J Clin Pharmacol* 58: 554-562 (2002).

---

Leenen FHH, Myers MG, Joyner CD, **Toal CB**: Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril. *Can J Cardiol* 18:1285-1293 (2002).

---

Xu C, Rao YS, Xu B, Hoffmann E, Jones JP, Sellers EM, **Tyndale RF**: An In Vivo Pilot Study Characterizing the New CYP2A6\*7, \*8, and \*10 alleles. *Biochem Biophys Res Comm* 290: 318-324 (2002).

Zhang W, Kilicarslan T, Ramamoorthy Y, Nolte H, **Tyndale RF**, Sellers EM: Inhibition of cytochrome P450s by antifungal imidazole derivatives. *Drug Metab Dispos*. 30(3): 314-8 (2002).

Pritzker D, Kanungo A, Kilicarslan T, **Tyndale RF**, Sellers EM: Designer drugs that are potent inhibitors of CYP2D6. *J Clin Psychopharmacol* 22: 330-332 (2002).

Fernandes LC, Kilicarslan T, Kaplan HL, **Tyndale RF**, Sellers EM, Romach MK: Treatment of codeine dependence with inhibitors of cytochrome P450 2D6 (CYP2D6). *J Clin Psychopharmacol* 22: 326-9 (2002).

Zhang W, Ramamoorthy Y, **Tyndale RF**, Glick SD, Maisonneuve IM, Kuehne ME, Sellers EM: Metabolism of 18-methoxycoronaridine, an Ibogaine analogue, to 18-hydroxy-coronaridine by genetically variable CYP2C19. *Drug Metab Dispos* 30: 663-669 (2002).

Ramamoorthy Y, Yu A, Suh N, Haining RL, **Tyndale RF**, Sellers EM: Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. *Biochem Pharmacol*. 63(12): 2111-9 (2002).

Miksys S, Rao Y, Hoffmann E, Sellers EM, Mash DM, **Tyndale RF**: Regional and cellular expression of cytochrome P450 2D6 in human brain: Higher levels in alcoholics. *J Neurochem* 82: 1-12 (2002).



Field JK, Brambilla C, Caporaso N, Flahault A, Henschke C, Herman J, Hirsch F, Lachmann P, Lam S, Maier S, Montuenga LM, Mulshine J, Murphy M, Pullen J, Spitz M, Tockman M, **Tyndale RF**, Wistuba I, Youngson J: Consensus statements from the 2nd Int. Lung Cancer Molecular Biomarkers Workshop: A European strategy for developing lung cancer molecular diagnostics in high risk populations. *Int J Oncol* 21:369-73 (2002).

O'Loughlin J, DiFranza J, Tarasuk J, Meshefedjian G, McMillan-Davey E, Paradis G, **Tyndale RF**, Clarke P, Hanley J: Assessment of nicotine dependence symptoms in adolescents: a comparison of five indicators. *Tobacco Control* 11:354-360 (2002)

Ahijevych K, Dhatt R, Kihm K, **Tyndale RF**, Wewers MD, Weed HG, Scalf S: Factors influencing Cotinine Elimination Trends in African American and Caucasian Women Cigarette Smokers. *Nicotine Tobacco* 4: 423-431 (2002).

Tyndale RF, Sellers EM: Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. *Therap Drug Monit* 24: 163-171 (2002).

Howard L, Sellers EM, **Tyndale RF**: Polymorphic CYP enzymes and Drug dependence. *Pharmacogenomics* 3: 185-199 (2002).

Miksys S, **Tyndale RF**: Drug-Metabolizing Cytochrome P450s in the Brain. *J Psychiat Neurosci*. 27: 406-415 (2002).

Xu C, Goodz S, Sellers EM, **Tyndale RF**: Pharmacogenetics of CYP2A6. *Adv Drug Deliv Rev* 54: 1245-56 (2002).

Goodz S, **Tyndale RF**: Methods for Genotyping CYP2A6. In: Methods in Enzymology 357:59-69 (2002).

Hong WK, **Tyndale RF**, Spitz M, Wu X, Wei Q, Hittelman W. The biology of tobacco and smoking. In: M.C. Perry (ed.). American Society of Clinical Oncology Education book. Lippincott Williams and Wilkins, Baltimore MD, 2002, pp 4-23.

---

## "U,V"

**Utrecht J**: N-Oxidation of drugs associated with idiosyncratic drug reactions. *Drug Metab Rev*. 34: 647-661 (2002).

Ju C, **Utrecht JP**: Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. *Curr Drug Metab*. 3: 367-377 (2002).

Iverson S, Zahid N, **Utrecht JP**: Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance



of an in vitro apoptosis assay for identifying drug that may cause agranulocytosis. *Chem-Biolog Interact* 142: 175-199 (2002).

Knowles SR, **Utrecht JP**, Shear NH: Confirming false adverse reactions to drugs by performing individualized, randomized trials. *Can J Clin Pharmacol*. 9: 149-153 (2002).

---

Lavine N, Ethier N, Oak JN, Trieu P, Rebois RV, Bouvier M, Hebert TE, **Van Tol HHM**: G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase. *J Biol Chem* 277: 46010-9 (2002).

Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, **Van Tol HHM**, MacDonald JF: A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. *Neuron*. 35: 1111-1122 (2002).

Thiyagarajan MM, Bigras E, **Van Tol HHM**, Hebert TE, Evanko DS, Wedegaertner PB: Activation-induced subcellular distribution of G alpha s is dependent on its unique N-terminus. *Biochemistry* 41: 9470-84 (2002).

Wong AHC, Klempan T, Kawczynski W, Barr CL, Lakatoo S, Wong M, Buckle C, Trakalo J, Boffa E, Oak JN, Azevedo M-H, Dourado A, Coelho I, Macedo A, Vicente A, Valente J, Ferreira CP, Pato CN, Kennedy JL, **Van Tol HHM**: The identification of candidate genes for psychosis in rat models, and possible association between schizophrenia and 14-3-3 $\eta$  gene. *Mol Psychiatry* 8: 156-166 (2002).

---

"W"

Sum CS, Park PS-H, **Wells JW**: Effects of N-ethylmaleimide on conformational equilibria in purified cardiac muscarinic receptors. *J Biol Chem*. 277: 36188-36203 (2002).

Park PS-H, Sum CS, Pawagi AB, **Wells JW**: Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. *Biochemistry* 41: 5588-5604 (2002).

---

Winn LM, **Wells PG**: Evidence for Ras-dependent signal transduction in phenytoin teratogenicity. *Toxicol Appl Pharmacol*. 184: 144-152 (2002).

Parman T, Wells PG: Embryonic prostaglandin H synthase-2 (PHS-2) expression and benzo[a]pyrene teratogenicity in PHS-2 knockout mice. *FASEB J*. 16: 1001-1009 (2002).

---

## "X,Y,Z"

**Zack M**, Toneatto T, MacLeod CM: Anxiety and explicit alcohol-related memory in problem drinkers. *Addictive Behaviors* 27: 331-343 (2002).

Breslin FC, **Zack M**, McMain S: An information processing analysis of mindfulness: Implications for relapse prevention in the treatment of substance abuse. *Clin Psychology: Sci Practice* 9: 275-299 (2002).

Cardenas L, Tremblay LK, Naranjo CA, Herrmann N, **Zack M**, Busto UE: Brain reward system activity in major depression and comorbid nicotine dependence. *J Pharmacol Exp Therap* 302: 1265-1271 (2002).

Weirs RW, Stacy AW, Ames SL, Noll JA, Sayette M, **Zack M**, Krank M: Implicit and explicit alcohol-related cognitions. *Alcoholism: Clin Exp Res* 26:129-137 (2002).

---